Published in Medical Letter on the CDC and FDA, January 14th, 2007
Patients receiving Aranesp were nearly three times more likely to achieve a hematopoietic response than patients receiving a placebo.
Researchers reported results for 218 patients treated with Aranesp (n=162) or placebo (n=56) for up to 17 weeks. The study's primary endpoint was the percentage of patients with a hematopoietic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.